Efficacious antitumor immune responses must overcome multiple suppressive mechanisms in the tumor microenvironment (TME) to control cancer progression. In this study, 
INTRODUCTION
To escape detection by the immune system, tumors foster an immunosuppressive environment and produce signals that subdue antitumor immune responses (1) . Tumorassociated macrophages (TAMs) are a heterogeneous population of myeloid cells that differentiate in the tumor microenvironment (TME) and become sensitized to tumor-derived suppressive signals (2) . TAMs, in turn, act to prevent local immune responses by inefficiently presenting antigen and generating suppressive signals such as IL10, indoleamine-pyrrole 2,3-dioxygenase (IDO), and TGFβ that inhibit lymphocyte function and metabolism (3) . Therefore, for adaptive immune responses to persist, tumor-infiltrating lymphocytes (TILs) must overcome a suppressive cytokine milieu and mechanisms of tolerance propagated by TAMs to successfully attack cancerous cells.
CSF-1 (M-CSF) is a cytokine that supports differentiation, proliferation, and function of monocyte and macrophage populations (4) . In tumors, CSF-1 promotes immune suppression by expanding and promoting differentiation of myeloid-derived suppressor cells (MDSCs) and alternatively activated MHC II lo TAMs that express its cognate receptor, CSF-1R (5, 6) . High CSF-1R expression on infiltrating immune cells in the TME correlates with immune dysfunction and increased immunosuppression (7, 8) , as well as poor prognosis in breast, ovarian, pancreatic cancers and lymphoma (9) (10) (11) . Although inhibiting the CSF-1/CSF-1R axis alone constrains tumor growth in preclinical models by partially decreasing TAMs and encouraging T cell infiltration (12) (13) (14) (15) (16) , it has often proven insufficient to clear tumors. Pairing CSF-1R blockade with chemotherapeutic agents or checkpoint inhibitors has enhanced efficacy of the monotherapy activity of CSF-1R (17) .
CD40 is a highly conserved costimulatory receptor expressed on antigen presenting cells (APCs) including dendritic cells (DCs), macrophages, monocytes, B cells, as well as a number of non-hematopoietic cell types and some tumor cells (18, 19) . The ligand for CD40 (CD40L) is expressed on activated T cells and B cells and, under inflammatory conditions, is upregulated on innate immune cells as well as endothelial and epithelial cells (20) (21) (22) (23) (24) . CD40
ligation drives "licensing" (maturation and activation) of APCs, enabling effective antigen presentation and stimulation of CD4 + Th1 and CD8 + T cells. This is a key step in mounting antitumor responses, as supported by emerging preclinical and clinical data with agonist anti-CD40 in multiple tumor types (18, 20, 25) . However, a number of studies have shown that potency of CD40 agonists can be enhanced by combinations with other immune modulatory therapies such as TLR agonists, cytokines including type I interferons and IL2, adoptive cell transfer, and chemotherapy (18, (26) (27) (28) (29) (30) . A study also demonstrated that CD40 agonism following 4 CSF-1R blockade leads to enhanced antitumor efficacy, suggesting these two therapies may cooperate when co-administered (30) .
In this study, we sought to investigate whether dual targeting of suppressive myeloid populations via CSF-1/CSF-1R inhibition and APC activation with agonist anti-CD40 treatment confers enhanced antitumor efficacy compared to monotherapy treatments. Tumor profiling after anti-CD40/anti-CSF-1R treatment revealed significant changes in the composition of CD11b CT26 and MC-38 cell lines were cultured in vitro under conditions specified by ATCC and passaged up to 3 times before implant. given at the same time but in separate injections on opposite sides of the abdomen (treatment was not premixed before injection). Doses were spaced four days apart for a total of three doses. CD8 + T-cell depletion studies were carried out with randomized groups of mice bearing CT26 tumors, which were treated with 200 μg anti-CD8 (clone 2.43; BioXcell) or PBS intraperitoneally 24 hours before immunotherapy was initiated and concurrently with immunotherapy. Dosing began day 11 and continued every four days as described above. For MC-38 tumor studies, female C57BL/6 mice, 6-9 weeks old, harboring MC-38 tumors 75-125 mm 3 in volume were randomized and treated identically to the CT26 studies.
MATERIALS AND METHODS

Tumor Cell Lines
CT26
Syngeneic Tumor Studies
Tumor and tissue processing
Tumors were excised and dissociated into single cell suspensions using the Miltenyi Tumor Dissociation Kit for murine tissues (catalog no. 130-096-730) per manufacturer's instructions. Samples were filtered and mechanically processed through 70 μm nylon filters. The following draining lymph nodes (dLNs) were pooled per mouse: ipsilateral, brachial, axillary, and inguinal lymph nodes. Spleens or pooled dLNs were processed through 70 μm nylon filters with syringe plungers. Samples were stained for flow cytometry the same day, and remaining suspensions were stored on ice at 4°C overnight for subsequent analyses.
Flow Cytometry and antibodies
For flow cytometry profiling, 2 x 10 6 tumor samples or 1 x 10 6 lymphoid tissue samples were plated in non-treated polystyrene round bottom 96-well plates (Corning 
Statistics and graphing with GraphPad Prism v6
On all graphs, mean and standard error of the mean (SEM) are shown unless otherwise indicated. Differences between treatment groups measured at endpoint were determined using analysis of variance (ANOVA) followed by post-hoc all-pairwise comparison tests with a Tukey adjustment for multiple comparisons. Survival analysis was performed using Logrank test.
Statistical analyses were run using GraphPad Prism version 6 (GraphPad Software, La Jolla, CA, USA). Statistical significance was accepted at p<0.05. All comparisons stated in results are versus isotype, unless otherwise specified.
RESULTS
Combined anti-CD40 and CSF-1R blockade improves tumor control and survival
Tumor-infiltrating myeloid cells, including TAMs, suppress antitumor immunity, and these populations rely on CSF-1/CSF-1R signaling for survival, development, and differentiation. To determine which myeloid subsets depend on the CSF-1/CSF-1R axis, CSF-1R expression was assessed in distinct populations of myeloid cells in established, untreated CT26 tumors. We used a gating strategy previously described by Movahedi et S1B ). Together, these expression profiles correlate with data in the literature and suggest mature TAMs would be sensitive to CSF-1R blockade.
We hypothesized that blocking the CSF-1/CSF-1R pathway in CT26 tumors would result in significant changes in TAMs, and that coupling CSF-1R inhibition with CD40 agonism would result in enhanced antitumor activity. Anti-CSF-1R monotherapy failed to significantly control CT26 tumor burden compared to isotype control, whereas anti-CD40 agonist treatment delayed tumor growth ( 
Combination immunotherapy results in reduced TAMs and alters myeloid populations
To understand mechanisms underlying the improved efficacy and survival mediated by We used Ly6C and Ly6G expression to subdivide CD11b + populations into monocytes, macrophages, and neutrophils and identified broad changes in the immune infiltrates across groups. Combination-treated tumors exhibited the greatest reduction in Ly6G + cells, which includes neutrophils and polymorphonuclear MDSCs, and Ly6C lo F4/80 + TAMs ( Fig. 2A-B ). In contrast, Ly6C hi cells increased significantly over isotype in all treatment groups. The greatest increase was seen in combination-treated tumors, which was also significantly greater than both monotherapies. (Fig. 2B ).
According to this model of subset analysis, the Ly6C + fraction consists of both monocytes and Ly6C int tumor associated macrophages, but the accumulation of Ly6C hi cells in combination-treated tumors was not due to proportionate increases of both cell types ( where four-fold more Ly6C int macrophages accumulated over the course of treatment compared to isotype controls and were significantly higher than both monotherapies. (Fig. 2E ). (Fig. 2G) . Together, these data indicate that anti-CSF-1R and CD40
agonism differentially affect TAM and monocyte populations and that anti-CD40/anti-CSF-1R combination treatment significantly skews the composition of tumor-infiltrating CD11b + myeloid cells. and MerTK compared to anti-CSF-1R and isotype groups (Fig. 3A-D) . Expression of inhibitory ligands, PD-L1 and PD-L2, did not change significantly across treatment groups in the majority of the experiments performed ( Fig. 3E-F) . In contrast, TAMs in anti-CD40 and combinationtreated tumors expressed markers consistent with activation (CD83) and maturation (CD80 and CD86) of pro-inflammatory MHC II hi macrophages (Fig. 3G-I) , with highest expression observed in anti-CD40 and combination-treated groups, consistent with CD40 ligation-induced activation (33) (Fig. 3G-I ). Anti-CSF-1R monotherapy elicited increased expression of CD80, CD86, and CD83 markers compared to isotype controls, but did not affect activation markers in alternatively (Fig. 3J-L) . Latency associated protein (LAP) was evaluated as a surrogate for the immunosuppressive cytokine TGFβ. Anti-CD40 and combination treatment decreased the fraction of TAMs poised to produce TGFβ in tumors, whereas anti-CSF-1R monotherapy was not appreciably different from isotype treatment. (Fig. 3M ).
CD40 agonism or combination immunotherapy increases pro-inflammatory TAMs
IL10/IL10R signaling is associated with suppression of antitumor immune responses (34, 35) . Reduced frequencies of IL10-producing TAMs were observed in all treated groups compared to isotype controls (Fig. 3N) , with only the combination-treated group reaching significance. Therefore, combination treatment reduced levels of LAP/TGFβ, IL10, and IL10R in suppressive TAM populations, increased frequencies of activated MHC II hi macrophages, and skewed the TME toward a pro-inflammatory phenotype.
Combination therapy induces accumulation of activated CD103 + DCs in dLNs
Efficient antigen presentation by DCs is critical to priming effective antitumor T-cell responses, and CD40 agonism is known to drive DC activation and maturation (36, 37) . In anti-CD40 or anti-CD40/anti-CSF-1R-treated tumors harvested after the end of treatment, CD83, CD80, and CD86 expression was increased on intratumoral DCs compared to isotype-treated DCs, whereas anti-CSF-1R monotherapy did not significantly change the activation status of these APCs (Fig. 4E ). tissues after activation via CD40 agonism and, therefore, examined dLNs 24 hours after the initial dose. Consistent with our hypothesis, significant DC accumulation was observed in the dLNs of animals treated with anti-CD40 or combination therapy but not anti-CSF-1R monotherapy (Fig. 4B) .
CD103 expression marks a subset of nonlymphoid classical DCs that have been implicated in cross presentation of tumor antigens and T-cell priming in lymphoid tissues (38, 39) . CD103 + DCs were reduced in tumors one day after anti-CD40 or combination treatment began but made up a significant fraction of total DCs in matched dLNs at the same time point (Fig. 4C-D) . A higher proportion of these DCs in the dLNs expressed markers of migration, and maturation: CCR7, CD83, CD80, and CD86 ( Fig. 4F-H 
Combined immunotherapy increased CD8+ TILs and enhanced CD8 + effector responses
We next investigated how improved antigen responses in dLNs of treated animals correlated to effector lymphocyte responses in tumors. First, we assessed frequencies of total T cells of CD45 + infiltrating immune cells in tumors. After treatment concluded, anti-CD40/anti-CSF-1R tumors contained more T cells on average than isotype-treated tumors, whereas anti-CSF-1R and anti-CD40 monotherapies drove smaller but reproducible increases in T-cell frequencies (Fig. 5G) Fig. S2C ). Moreover, absolute number of CD8 + T cells was increased per gram of tumor after combination or anti-CD40 treatment ( Supplementary Fig. S2F ). These data demonstrate that more CD8 + T cells infiltrate tumors after agonist CD40 or CSF-1R blockade, but the combination is more effective than either monotherapy. Unlike the findings in dLNs, the proportion of AH1 tetramer + CD8 + cells was not significantly altered in tumors across treatment groups (Fig. 5I) .
To determine whether intratumoral T-cell effector responses improved with combination immunotherapy, we assessed the phenotype and function of CD8 + TILs in CT26 tumors by assessing expression of activation markers in total CD8 + TILs and AH1 tetramer + CD8 + T cells.
Similar to CD8 + T cells in dLNs, activation markers and checkpoint molecules, PD-1, TIM-3, TIGIT, and Lag3, were increased on CD8 + TILs after anti-CD40 or combination immunotherapy, relative to isotype-treated tumors ( Supplementary Fig. S3G-H TILs co-expressed multiple checkpoint molecules, indicating enhanced effector activation ( Supplementary Fig. S3H ).
Restimulation with AH1 peptide ex vivo revealed that anti-CD40/anti-CSF-1R combination immunotherapy elicited significantly higher frequencies of antigen-specific CD8 + TILs primed to produce IFNγ, TNFα, or granzyme B in response to tumor antigen (Fig. 5J) . A higher proportion of CD8 + TILs from combination-treated tumors were also able to mount polyfunctional responses in response to AH1 peptide (Fig. 5J) . Together, these data suggest that anti-CD40/anti-CSF-1R immunotherapy enhances both the quality and quantity of CD8 + TILs.
Tumor-infiltrating regulatory T cells are decreased in tumors with combination treatment
Anti-CD40/anti-CSF-1R treatment resulted in increased frequencies and improved function of CD8 + TILs, as well as decreased frequencies of Foxp3 -conventional CD4 + TILs. (Fig. 6A-B) . Anti-CSF-1R monotherapy had a role in driving improved CD4 + helper responses compared to isotype controls (Fig. 6B ).
Previous reports described decreased immunosuppressive Foxp3 + Tregs in tumor models after either anti-CSF-1R or anti-CD40 treatment (40, 41) . We assessed whether similar changes were observed in this subset of T cells after anti-CD40/anti-CSF-1R treatment. Supplementary Fig. S2E ), and the most dramatic decrease was seen after anti-CD40/anti-CSF-1R combination treatment, which had a higher helper CD4 + T-cell:Treg ratio in combinationtreated animals. A four-fold higher ratio of CD8 + TILs to Tregs was seen in combination-treated tumors compared to isotype controls (Fig. 6F) . Although frequencies of AH1 tetramer + CD8 + TILs did not significantly change, combination treatment resulted in a significantly higher ratio of AH1-specific CD8 + TILs to Tregs (Fig. 6G) . Together, these data suggest that helper CD4 + TILs and effector CD8 + TILs may be able to sustain improved antitumor functions due to the decreased Treg frequency in the TME.
Consistent with published data, tumors treated with either anti-CSF-1R or anti-CD40
The cytokine milieu is more inflammatory with combination treatment
Changes we observed in both myeloid and lymphoid populations demonstrate that anti-CD40/anti-CSF-1R immunotherapy resulted in significant alterations to the immune infiltrate in CT26 tumors. To determine the sum effect of the observed changes on the TME cytokine milieu, we measured cytokine analytes in homogenized tumors and normalized analyte concentration per gram of tumor harvested. Pro-inflammatory cytokines TNFα, IFNγ, IL6, IL23, and IL12 were increased in tumors that received anti-CD40 or combination immunotherapy ( Supplementary Fig. S4A ). In anti-CD40 or combination-treated tumors, increased GM-CSF was also observed, which supports MHC II hi TAM polarization. In contrast, levels of immunosuppressive cytokine IL10 were decreased in all treatment groups compared to isotypetreated tumors, including anti-CSF-1R treatment alone ( Supplementary Fig. S4B ). Mean levels of IL4 was also reduced ~30% in anti-CD40 and combination-treated tumors compared to isotype controls, but the amount of IL4 was relatively minimal in all groups ( Supplementary Fig.   S4B ). These data suggest that the total effect of combination treatment skewed the TME towards increased inflammatory cytokine production and reduced suppressive signals. Together, the phenotype and functional analysis of TAMs, monocytes, and tumor-infiltrating T cells demonstrate that anti-CD40/anti-CSF-1R immunotherapy drives a cumulative polarization of the TME towards an antitumor, pro-inflammatory environment, resulting in improved immune responses, overall enhanced antitumor efficacy, and extended survival.
DISCUSSION
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